Production (Stage)
CYduct Diagnostics, Inc.
CYDX
$0.2031
$0.0010.50%
OTC PK
| 03/31/2012 | 12/31/2011 | 09/30/2011 | 06/30/2011 | 03/31/2011 | |
|---|---|---|---|---|---|
| Revenue | 20.12% | -13.64% | -34.43% | -18.74% | -23.19% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 20.12% | -13.64% | -34.43% | -18.74% | -23.19% |
| Cost of Revenue | -0.54% | 210.45% | -45.97% | 14.51% | -24.17% |
| Gross Profit | 37.44% | -51.58% | -27.50% | -40.23% | -22.34% |
| SG&A Expenses | -75.61% | -82.80% | -7.09% | -22.90% | 60.91% |
| Depreciation & Amortization | -- | -100.00% | -66.67% | -33.33% | -43.18% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -71.01% | -78.03% | -13.37% | -18.21% | 47.92% |
| Operating Income | 85.92% | 90.61% | 1.35% | 17.94% | -74.26% |
| Income Before Tax | 125.75% | 127.32% | 131.65% | 18.96% | -71.22% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 125.75% | 127.32% | 131.65% | 18.96% | -71.22% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 125.75% | 127.32% | 131.65% | 18.96% | -71.22% |
| EBIT | 85.92% | 90.61% | 1.35% | 17.94% | -74.26% |
| EBITDA | 86.39% | 90.50% | -0.93% | 17.41% | -78.03% |
| EPS Basic | -- | -- | -- | -- | -- |
| Normalized Basic EPS | -- | -- | -- | -- | -- |
| EPS Diluted | -- | -- | -- | -- | -- |
| Normalized Diluted EPS | -- | -- | -- | -- | -- |
| Average Basic Shares Outstanding | -- | -- | -- | -- | -- |
| Average Diluted Shares Outstanding | -- | -- | -- | -- | -- |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |